Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Aging
Interventions: Multifactorial Falls Assessment; Other
Lead sponsor: Powers, James S., M.D.; Individual
Eligibility: 65 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Carpal Tunnel
Interventions: Narcotic, non-narcotic; Drug
Lead sponsor: Horizon Health Network; Other
Eligibility: 18 Years to 90 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Sioux Falls, South Dakota • Roanoke, Virginia

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 38
States / cities: Beverly Hills, California • Chino, California • Costa Mesa, California + 32 more

Conditions: Dry Eye Syndrome
Interventions: EBI-005-2; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 8
States / cities: Artesia, California • Ranchero Cordova, California • Torrence, California + 5 more

Conditions: Eponychial Stent, Nail Bed Injury
Interventions: Nail bed repair with eponychial sent, Nail bed repair without eponychial stent; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: New York, New York • Richmond Hill, New York

Conditions: Methodology Study
Interventions: placebo, zolpidem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Vegetables, Cardiovascular Disease, Blood Pressure
Interventions: Vegetable Juice; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Davis, California

Conditions: Chronic Ankle Instability, Ankle Sprains, Ankle Rehabilitation
Interventions: Resistance Band Ankle Rehabilitation, Biomechanical Ankle Platform System Rehabilitation, Combination Rehabilitation; Other
Lead sponsor: Georgia State University; Other
Eligibility: 15 Years to 18 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Atlanta, Georgia • College Park, Georgia • Decatur, Georgia + 1 more

Conditions: Keratoconus
Interventions: GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Male Pattern Hair Loss
Interventions: HST 001, Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Osteoporosis
Interventions: Low Na diet (1.3 g/d), High sodium diet (3.8 g/d); Other
Lead sponsor: Purdue University; Other
Eligibility: 11 Years to 15 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions: Denosumab, Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 30 Years to 120 Years · Male only
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 52
States / cities: Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions: oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 30
States / cities: Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Obesity, Overweight
Interventions: HPP404, Placebo; Drug
Lead sponsor: High Point Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Augusta, Georgia • Valparaiso, Indiana • Louisville, Kentucky + 7 more

Conditions: Healthy
Interventions: L-Ergothioneine 10 mg/d, L-Ergothioneine 25 mg/d, Placebo; Dietary Supplement · Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 55 Years to 79 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 16 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 25
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 16 more

Conditions: Migraine Disorders, Headache Disorders
Interventions: SPN-538, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo for dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more

Conditions: Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
Interventions: Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes (DM)
Interventions: Food is medicine; Dietary Supplement
Lead sponsor: Public Health Institute Center for Wellness and Nutrition; Other
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Stockton, California

Conditions: Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions: AXS-12 (Reboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more

Conditions: Graft vs Host Disease
Interventions: ASEDs, Saline; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 29
States / cities: Escondido, California • Greenbrae, California • Los Angeles, California + 25 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Spartalizumab, Capmatinib, spartalizumab placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Longitudinal Outcome in a Veterans Geriatric Multifactorial Falls Assessment Clinic

Narcotic vs. Non-narcotic Pain Study Protocol

Safety and Efficacy of Vilazodone in Major Depressive Disorder

A Multi-Center Study Subjects With Dry Eye Syndrome

Eponychial Stent Study

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

Clinical Investigation on the Effects of a Vegetable Juice Treatment

A Study Investigating The Effects Of An Ankle Rehabilitation Program On High School Athletes With Ankle Instability

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

Effect of Sodium Intake on Calcium Retention in Girls

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Therapy for Migraine Prevention in Children 6-11 Years of Age

Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients

Evaluation of the Impact of a Food is Medicine Program on Diabetes-related Health Outcomes for People With Type 2 Diabetes in a Low Income Community-based Setting Compared to Usual Care

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations